Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 10c, Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Jazz Pharmaceuticals (JAZZ) Price Target Raised to $190 at UBS
November 5, 2014 9:11 AM ESTUBS maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) and raised its price target to $190.00 (from $180.00). The change follows Q3 results.
Analyst Marc Goodman said, "It was another solid quarter, and Jazz has clearly demonstrated that 1Q was an anomaly. Xyrem... More
